J. Madelaine

987 total citations
33 papers, 406 citations indexed

About

J. Madelaine is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Epidemiology. According to data from OpenAlex, J. Madelaine has authored 33 papers receiving a total of 406 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Pulmonary and Respiratory Medicine, 18 papers in Oncology and 7 papers in Epidemiology. Recurrent topics in J. Madelaine's work include Lung Cancer Treatments and Mutations (17 papers), Lung Cancer Research Studies (8 papers) and Neuroendocrine Tumor Research Advances (6 papers). J. Madelaine is often cited by papers focused on Lung Cancer Treatments and Mutations (17 papers), Lung Cancer Research Studies (8 papers) and Neuroendocrine Tumor Research Advances (6 papers). J. Madelaine collaborates with scholars based in France, United States and Spain. J. Madelaine's co-authors include Nicolas Aide, Pascal Dô, Charline Lasnon, Gérard Zalcman, Dimitris Visvikis, Marion Sassier, Mohamed Majdoub, Mathieu Hatt, Stéphane Éderhy and François Comoz and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Respiratory Journal.

In The Last Decade

J. Madelaine

29 papers receiving 404 citations

Peers

Countries citing papers authored by J. Madelaine

Since Specialization

Citations

This map shows the geographic impact of J. Madelaine's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Madelaine with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Madelaine more than expected).

Fields of papers citing papers by J. Madelaine

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Madelaine. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Madelaine. The network helps show where J. Madelaine may publish in the future.

Co-authorship network of co-authors of J. Madelaine

This figure shows the co-authorship network connecting the top 25 collaborators of J. Madelaine. A scholar is included among the top collaborators of J. Madelaine based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Madelaine. J. Madelaine is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO) 2022 ·Lung Cancer ·Benjamin Levy, Fabrice Barlési, Luis Paz‐Ares, Jaafar Bennouna, Mustafa Erman, Enriqueta Felip, Dolores Isla, Hye Ryun Kim, Sang‐We Kim, J. Madelaine, Olivier Molinier, Mustafa Özgüroğlu, Delvys Rodríguez‐Abreu, Abidemi Adeniji, Robert M. Lorence, Isabelle Voccia, Michael Chisamore, Jonathan W. Riess	6
2	Molecular Alterations in Malignant Pleural Mesothelioma: A Hope for Effective Treatment by Targeting YAP 2022 ·Targeted Oncology ·Fatéméh Dubois, Céline Bazille, Jérôme Levallet, (unknown), Solenn Brosseau, J. Madelaine, Emmanuel Bergot, Gérard Zalcman, Guénaëlle Levallet	8
3	Outcome of Patients With Resected Early-Stage Non-small Cell Lung Cancer and EGFR Mutations: Results From the IFCT Biomarkers France Study 2022 ·Clinical Lung Cancer ·Pierre Mordant, Solenn Brosseau, B. Milleron, Nicola Santelmo, (unknown), Benjamin Besse, Alexandra Langlais, Dominique Gossot, P. Thomas, Jean-Louis Pujol, Charles Ricordel, J. Madelaine, R. Lamy, Clarisse Audigier-Valette, Pascale Missy, Hélène Blons, Fabrice Barlési, Virginie Westeel	4
4	Atteinte pulmonaire de pyoderma gangrenosum : discussion diagnostique et thérapeutique à partir d’un cas et d’une revue ciblée de la littérature 2021 ·La Revue de Médecine Interne ·(unknown), J. Madelaine, G. Planchard, Alexandre Dumont, Alexandra Audemard‐Verger, (unknown), Emmanuel Bergot, Achille Aouba	1
5	LBA41 Nivolumab (nivo) ± ipilimumab (ipi) in pre-treated patients with advanced, refractory pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine tumors (NECs) (GCO-001 NIPINEC) 2021 ·Annals of Oncology ·Nicolas Girard, Julien Mazières, Josiane Otto, H. Léna, C. Lepage, Thomas Egenod, Denis Smith, J. Madelaine, L. Gérinière, Farid El Hajbi, Aurélie Ferru, Christelle Clément-Duchêne, Anne Madroszyk, Jérôme Desrame, Franck Morin, Alexandra Langlais, Pierre Michel, Christophe Louvet, Virginie Westeel, Thomas Walter	19
6	Étude D-CBP : Évaluation des délais de prise en charge du cancer broncho- pulmonaire au sein du service de Pneumologie et d’Oncologie Thoracique du CHU de Caen 2021 ·Revue des Maladies Respiratoires ·Samuel Deshayes, (unknown), J. Madelaine, Youssef Oulkhouir, Katrina Campbell, (unknown), (unknown), (unknown), (unknown), D. Lerouge, Emmanuel Bergot, A. Justet	1
7	Combination of trastuzumab, pertuzumab and docetaxel in patients with advanced non-small cell lung cancer (NSCLC) harboring HER2 mutation: Final results from the IFCT-1703 R2D2 trial. 2021 ·Journal of Clinical Oncology ·Julien Mazières, (unknown), Charles Ricordel, Laurent Greillier, Jean-Louis Pujol, Gérard Zalcman, Charlotte Domblides, J. Madelaine, Jaafar Bennouna, Céline Mascaux, Denis Moro‐Sibilot, (unknown), Alexis B. Cortot, Josiane Otto, J. Cadranel, Alexandra Langlais, Franck Morin, Virginie Westeel, Benjamin Besse	5
8	LBA84 Consolidation ipilimumab and nivolumab vs observation in limited stage SCLC after chemo-radiotherapy: Results from the ETOP/IFCT 4-12 STIMULI trial 2020 ·Annals of Oncology ·Solange Peters, J.L. Pujol, Urania Dafni, Manuel Dómine, (unknown), J. Andrade, Alessandra Curioni‐Fontecedro, O. Molinier, Denis Moro‐Sibilot, Kristiaan Nackaerts, (unknown), Guillermo López-Vivanco, J. Madelaine, Sanjay Popat, Martin Reck, Heidi Roschitzki‐Voser, Paul Mitchell, Dirk De Ruysscher, C. Le Péchoux, Rolf A. Stahel	12
9	LBA3_PR An international randomized trial, comparing post-operative conformal radiotherapy (PORT) to no PORT, in patients with completely resected non-small cell lung cancer (NSCLC) and mediastinal N2 involvement: Primary end-point analysis of LungART (IFCT-0503, UK NCRI, SAKK) NCT00410683 2020 ·Annals of Oncology ·C. Le Péchoux, N. Pourel, Fabrice Barlési, Corinne Faivre‐Finn, D. Lerouge, Gérard Zalcman, D. Antoni, (unknown), Ursula Nestle, (unknown), F. Thillays, A. Paumier, Éric Dansin, Karine Peignaux, J. Madelaine, Éric Pichon, Anne Larrouy, Oliver Riesterer, A. Lavolé, A. Bardet	60
10	Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol 2019 ·Clinical Lung Cancer ·Benjamin Levy, Luis Paz‐Ares, Jaafar Bennouna, Enriqueta Felip, Delvys Rodríguez‐Abreu, Dolores Isla, Fabrice Barlési, Olivier Molinier, J. Madelaine, Clarisse Audigier-Valette, Sang-We Kim, Hye Ryun Kim, Mustafa Özgüroğlu, Mustafa Erman, Firas Badin, Tarek Mekhail, Ronald Scheff, Michael Chisamore, (unknown), Jonathan W. Riess	8
11	Real-Life Efficacy of Osimertinib in Pretreated Octogenarian Patients with T790M-Mutated Advanced Non-small Cell Lung Cancer 2019 ·Targeted Oncology ·J.B. Auliac, (unknown), M. André, J. Madelaine, Gilles Quéré, Philippe Masson, A. Vergnenègre, R. Lamy, (unknown), (unknown), Pierre-Alexandre Hauss, P. Fournel, R. Corre, C. Chouaïd	7
12	Maintenance chemotherapy versus follow-up after carboplatin and weekly paclitaxel doublet chemotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC): IFCT-1201 MODEL randomised phase III trial 2018 ·Annals of Oncology ·Élisabeth Quoix, Clarisse Audigier-Valette, A. Lavolé, Olivier Molinier, Virginie Westeel, Fabrice Barlési, J. Le Treut, Éric Pichon, Jérôme Dauba, Josiane Otto, Patrick Dumont, L. Moreau, J. Madelaine, J. Margery, D. Debieuvre, (unknown), Alexandra Langlais, Franck Morin, Denis Moro‐Sibilot, P.-J. Souquet	0
13	Afatinib in combination with pembrolizumab in patients (pts) with stage IIIB/IV squamous cell carcinoma (SCC) of the lung. 2018 ·Journal of Clinical Oncology ·Benjamin Levy, Luis Paz‐Ares, Jaafar Bennouna, Enriqueta Felip, Delvys Rodríguez‐Abreu, Dolores Isla, Fabrice Barlési, Olivier Molinier, J. Madelaine, Clarisse Audigier-Valette, Sang‐We Kim, Mustafa Özgüroğlu, Mustafa Erman, Firas Badin, Tarek Mekhail, Ronald Scheff, Jonathan W. Riess	1
14	Generating harmonized SUV within the EANM EARL accreditation program: software approach versus EARL-compliant reconstruction 2016 ·Annals of Nuclear Medicine ·Charline Lasnon, (unknown), Cédric Desmonts, Pascal Dô, Youssef Oulkhouir, J. Madelaine, Nicolas Aide	34
15	18F-FDG PET/CT heterogeneity quantification through textural features in the era of harmonisation programs: a focus on lung cancer 2016 ·European Journal of Nuclear Medicine and Molecular Imaging ·Charline Lasnon, Mohamed Majdoub, (unknown), Pascal Dô, J. Madelaine, Dimitris Visvikis, Mathieu Hatt, Nicolas Aide	45
16	Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with docetaxel in KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial. 2013 ·Journal of Clinical Oncology ·David R. Gandara, Sandrine Hiret, George R. Blumenschein, Fabrice Barlési, Jean‐Pierre Delord, J. Madelaine, Jeffrey R. Infante, Karen L. Reckamp, Primo N. Lara, Christine Audebert, Byoung Chul Cho, Keunchil Park, Fadi S. Braiteh, Robert M. Jotte, Yuehui Wu, Daniel Schramek, (unknown), Olivia Gardner, (unknown), Natasha B. Leighl	23
17	Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3 2011 ·European Respiratory Journal ·Isabelle Borget, Jacques Cadranel, Jean‐Pierre Pignon, Élisabeth Quoix, Bruno Coudert, Virginie Westeel, Éric Dansin, J. Madelaine, Anne Madroszyk, S. Friard, Catherine Daniel, Franck Morin, C. Chouaïd, (unknown)	27
18	[Primitive metastasizing bronchial carcinoid with long survival]. 2007 ·PubMed ·Nancy Bouvier, (unknown), (unknown), (unknown), (unknown), J. Madelaine, Françoise Galateau-Sallé, Emmanuel Bergot, Gérard Zalcman	3
19	Carcinoïde bronchique d’emblée multimétastatique et survie prolongée 2007 ·Revue des Maladies Respiratoires ·Nicolas Bouvier, (unknown), (unknown), V. Le Pennéc, (unknown), J. Madelaine, Françoise Galateau-Sallé, Emmanuel Bergot, Gérard Zalcman	4
20	Hydratation des patients sous cisplatine : enquête de pratiques et élaboration d’un protocole 2005 ·Therapies ·(unknown), J. Madelaine, Marie‐Pierre Galais, Thierry Lobbedez, (unknown)	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact